| Species |
Human |
| Protein Construction |
| His |
ANXA2 (Ser2-Asp339)
Accession # P07355 |
| N-term |
C-term |
|
| Purity |
> 95% as determined by Bis-Tris PAGE |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Expression System |
E.coli |
| Theoretical Molecular Weight |
39.6 kDa |
| Apparent Molecular Weight |
The protein has a predicted MW of 39.6 kDa same as Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
ANXA2, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
| Target Background |
ANXA2, highly expressed in invasive breast cancer cells, is closely related with poor prognosis, and acts as a molecular switch to EGFR activation. ANXA2 expression is inversely correlated with cell sensitivity to gefitinib. Knockdown of ANXA2 expression in MDA-MB-231 cells increased the gefitinib induced cell death. When ANXA2 was overexpressed in MCF7 cells, the gefitinib induced cell death was decreased. Furthermore, the phosphorylation of ANXA2 at Tyr23 is negatively correlated with the sensitivity of TNBC to gefitinib. |
| Synonyms |
Chromobindin-8; Lipocortin II; PAP-IV; ANX2; ANX2L4; CAL1H; LPC2D; ANXA2; Annexin A2; Annexin II; LIP2PAP-IV; LPC2D; LPC2DP36; p36 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
